Volume | 876,083 |
|
|||||
News | - | ||||||
Day High | 2.3577 | Low High |
|||||
Day Low | 2.15 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GlycoMimetics Inc | GLYC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.29 | 2.15 | 2.3577 | 2.16 | 2.28 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,122 | 876,083 | $ 2.24 | $ 1,964,521 | - | 1.11 - 3.5299 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:30:27 | 76 | $ 2.16 | USD |
GlycoMimetics (GLYC) Options Flow Summary
GlycoMimetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
138.45M | 64.39M | - | 10k | -36.9M | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GlycoMimetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLYC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.57 | 2.57 | 2.14 | 2.31 | 632,924 | -0.41 | -15.95% |
1 Month | 3.03 | 3.18 | 2.14 | 2.65 | 546,637 | -0.87 | -28.71% |
3 Months | 3.07 | 3.50 | 2.14 | 2.84 | 393,107 | -0.91 | -29.64% |
6 Months | 1.41 | 3.5299 | 1.11 | 2.64 | 310,228 | 0.75 | 53.19% |
1 Year | 1.56 | 3.5299 | 1.11 | 2.30 | 241,226 | 0.60 | 38.46% |
3 Years | 2.59 | 4.16 | 0.51 | 2.11 | 431,021 | -0.43 | -16.60% |
5 Years | 11.96 | 13.41 | 0.51 | 3.07 | 470,596 | -9.80 | -81.94% |
GlycoMimetics Description
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. |